Clinical trials: Efavirenz
HIV
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
1. To see how the liver breaks down efavirenz by an enzyme called CYP2B6. It is suggested that when Efavirenz is taken repeatedly it may increase the amount of CYP2B6 in your liver and thus speed up your liver's ability to get…
- Trial name
- NCT00668395
- Testing
- Efavirenz
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Indiana University
Pancreatic Cancer
Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with…
- Trial name
- PANTER (NCT00964171)
- Testing
- Efavirenz 600mg
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Institut Bergonié
HIV Infections
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
The hypothesis tested in this study is that doravirine (MK-1439) at the final dose selected is superior to efavirenz, each given in combination with TRUVADA®, as measured by the percentage of participants with CNS events by Week…
- Trial name
- NCT01632345
- Testing
- Doravirine, Efavirenz, TRUVADA®
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.
Clinical data suggests that the standard dose of the anti-HIV medication, efavirenz (EFV), could be reduced without compromising its effectiveness.
- Trial name
- ENCORE1 (NCT01011413)
- Testing
- Efavirenz 600mg, Efavirenz 400mg
- Where
- Australia
- Volunteers
- 636 people
- Sponsor
- Kirby Institute
HIV
Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
A study will be conducted by scientists from the University of Zimbabwe to determine if antiretroviral drugs are affected by taking herbs at the same time.
- Trial name
- NCT01410058
- Testing
- Moringa oleifera, Efavirenz 600mg, Nevirapine 200Mg Oral Tablet
- Where
- Zimbabwe
- Volunteers
- 19 people
- Sponsor
- University of Zimbabwe
Healthy
CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
The CYP2B6 enzyme metabolizes a growing number of clinically important drugs such as the anti-HIV drug efavirenz, but its activity in the liver is highly variable, which may lead to failure of therapy or toxicity and…
- Trial name
- NCT02401256
- Testing
- Efavirenz, Bupropion, Rosuvastatin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV-1
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MERIT (NCT00098293)
- Testing
- Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
- Where
- 144 sites in United States, Argentina and 12 more
- Volunteers
- 916 people
- Sponsor
- ViiV Healthcare
HIV Infections, HIV-1
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a background regimen…
- Trial name
- NCT00543725
- Testing
- TMC278, efavirenz
- Where
- 82 sites in United States, Australia and 18 more
- Volunteers
- 680 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic, HIV Infection
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
The main objective is to evaluate the hepatic safety of raltegravir when compared to efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment in patients with HIV and hepatitis C coinfection.
- Trial name
- NCT01147107
- Testing
- Raltegravir, Efavirenz
- Where
- 2 sites in Vietnam
- Volunteers
- 80 people
- Sponsor
- University of Hawaii
HIV Infection, Mitochondrial Dysfunction
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1.
- Trial name
- NCT01194856
- Testing
- Atazanavir/ritonavir, Efavirenz
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Cleveland Clinic
HIV Infections, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients.
- Trial name
- NCT00100048
- Testing
- Comparator: MK0518 monotherapy, Comparator: MK0518 combination therapy, Comparator: efavirenz
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute HIV Infection, HIV Infections
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
This is a pilot study of treatment of acute HIV infection with a once daily regimen of Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are: 1.
- Trial name
- NCT00924898
- Testing
- efavirenz, emtricitabine, and tenofovir
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of North Carolina, Chapel Hill